

North Central Cancer Treatment Group

N027D      A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation  
Therapy in Glioblastoma Multiforme

Status Change – July 13, 2007

**NOTICE OF STATUS CHANGE**

The study is reopening to Mayo (Jacksonville, Rochester, Scottsdale) and the University of Alabama at Birmingham at dose level 2 (75mg/week CCI-779, 6000cGy RT, 75 mg/m<sup>2</sup>/day TMZ) for another 3 patients effective July 13, 2007.

**Please retain this notice with the protocol.**